Opko Health Inc
USUSDOpko Health Inc (US:OPK) — Biotechnology: Pharmaceutical Preparations. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 2. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par Uzņēmumu
- Tīmekļvietne
- opko.com
- Investoru Attiecības
- opko.com/investors
- Nozare
- Health Care · Biotechnology: Pharmaceutical Preparations
- Galvenā Mītne
- Miami, United States
- Izpilddirektors
- Phillip Frost
- Darbinieki
- 2 275
- Dibināts
- 1991
- Apgrozībā Esošās Akcijas
- 746.33 milj. uz 2026-07-17
- Brīvā Apgrozība
- 323.73 milj.
- Tirgus Kapitalizācija
- 1.17 mljrd. USD
- Iekšējās Personas
- 50.52%
- Institucionālie Investori
- 27.56%
- Nozare (SIC)
- Pharmaceutical Preparations
- ISIN
- US68375N1037
- LEI
- 529900A4S2D4OGOJLL02
- P/E
- zaudējumi
- FCF
- −134 milj. USD
- Parāds
- 349 milj. USD
- Peļņa un FCF — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Lielākie Akcionāri
| Turētājs | Daļa | Akcijas | Pārskata Datums |
|---|---|---|---|
| Rubric Capital Managemen… | 6.4% | 47.79 milj. | 2026-06-30 |
| Blackrock Inc. | 4.95% | 36.98 milj. | 2026-06-30 |
| Vanguard Capital Managem… | 2.01% | 14.97 milj. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2% | 14.93 milj. | 2026-06-30 |
| Geode Capital Management… | 1.55% | 11.58 milj. | 2026-06-30 |
| iShares Trust-iShares Ru… | 1.38% | 10.32 milj. | 2026-08-31 |
| State Street Corporation | 1.38% | 10.31 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.31% | 9.75 milj. | 2026-06-30 |
| Goldman Sachs Group Inc | 0.94% | 7.04 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.93% | 6.92 milj. | 2026-06-30 |
| UBS Group AG | 0.67% | 5.01 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.66% | 4.91 milj. | 2026-06-30 |
| Whitefort Capital Manage… | 0.6% | 4.51 milj. | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.58% | 4.35 milj. | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.51% | 3.79 milj. | 2026-08-31 |
| Northern Trust Corporati… | 0.5% | 3.76 milj. | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.38% | 2.81 milj. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.29% | 2.2 milj. | 2026-06-30 |
| VANGUARD SCOTTSDALE FUND… | 0.28% | 2.11 milj. | 2026-05-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.27% | 2.04 milj. | 2026-05-31 |
| PAGANELLI JOHN A (Direct… | ≈0.05% | 403 515 | 2026-03-20 |
| FROST PHILLIP MD ET AL (… | — | — | 2025-11-21 |
Pieslēdzies ar Google